Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
10 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
14
14 articles ont été cités au moins 14fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
943
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
75
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
16
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Charles-Nicolle · Université de Rouen Normandie
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing ≥ 50% PD-L1 (ESCKEYP GFPC 05-2018)
2025ArticleClinical Lung Cancer
Hypnosis associated with 3D immersive virtual reality technology during bronchoscopy under local anesthesia
2022ArticleJournal of Thoracic Disease
Endoscopic Follow-up of Low Grade Precancerous Bronchial Lesions in High-Risk Patients: long-term results of the SELEPREBB randomized multicentre trial
2022ArticleEuropean Respiratory Journal
A simple endoscopic method with radial endobronchial ultrasonography for low-migration rate coil-tailed fiducial marker placement
2020ArticleJournal of Thoracic Disease
Assessment of Per-Endoscopic Placement of Fiducial Gold Markers for Small Peripheral Lung Nodules < 20 mm Before Stereotactic Radiation Therapy
2018ArticleChest
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
2017ArticleJournal of Thoracic Oncology
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study
2016ArticleJournal of Clinical Oncology
Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
2011ArticleJournal of Thoracic Oncology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL CHARLES NICOLLE CHU ROUEN
1 R DE GERMONT, 76000 ROUEN
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Paris Normandie · 21/02/2018
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOS2kwV1RzWEtsTmlJSzNfYzYzczc0WlRSVXA3LUdNNWJaZk1LTFlNUlJWdWgzSmdUbHNSSThTTVFCb0NkWTk1TUxFXzY0dUdMam1CTF9TZmpxdWdyeEZqcERTSXVxT3gtZEM5Sl9tYWZUNlZZMUZobnU4TmlPX3J3TE1Xd0lzWWV2RlVUS0VRbkRaZ1JwSDBOQS03SUNLM2l1Z3h5aEotS3p3bXZOeVJMOFVCaEZWQ0w2VV
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
Purpose Comprehensive geriatric assessment (CGA) is recommended to assess the vulnerability of elderly patients, but its integration in cancer treatment decision making has never been prospectively evaluated. Here, in elderly patients with advanced non–small-cell lung cancer (NSCLC), we compared a standard strategy of chemotherapy allocation on the basis of performance status (PS) and age with an experimental strategy on the basis of CGA. Patients and Methods In a multicenter, open-label, phase III trial, elderly patients ≥ 70 years old with a PS of 0 to 2 and stage IV NSCLC were randomly assigned between chemotherapy allocation on the basis of PS and age (standard arm: carboplatin-based doublet if PS ≤ 1 and age ≤ 75 years; docetaxel if PS = 2 or age > 75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive care for frail patients). The primary end point was treatment failure free survival (TFFS). Secondary end points were overall survival (OS), progression-free survival, tolerability, and quality of life. Results Four hundred ninety-four patients were randomly assigned (standard arm, n = 251; CGA arm, n = 243). Median age was 77 years. In the standard and CGA arms, 35.1% and 45.7% of patients received a carboplatin-based doublet, 64.9% and 31.3% received docetaxel, and 0% and 23.0% received best supportive care, respectively. In the standard and CGA arms, median TFFS times were 3.2 and 3.1 months, respectively (hazard ratio, 0.91; 95% CI, 0.76 to 1.1), and median OS times were 6.4 and 6.1 months, respectively (hazard ratio, 0.92; 95% CI, 0.79 to 1.1). Patients in the CGA arm, compared with standard arm patients, experienced significantly less all grade toxicity (85.6% v 93.4%, respectively P = .015) and fewer treatment failures as a result of toxicity (4.8% v 11.8%, respectively; P = .007). Conclusion In elderly patients with advanced NSCLC, treatment allocation on the basis of CGA failed to improve the TFFS or OS but slightly reduced treatment toxicity.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011
American journal of respiratory and critical care medicine · 2008
Abstract Rationale The outcome of precancerous bronchial lesions is not well known, and their management is subject to controversy. Many molecular alterations are present in preinvasive lesions, but none has been assessed to predict the evolution of the lesions. Objectives To analyze the outcome of high-grade precancerous lesions according to their molecular profile. Methods Twenty-three severe dysplasia and 31 carcinoma in situ (CIS) lesions in 37 patients were monitored using repeated autofluorescence bronchoscopy over a 12-year period. Microdissection and polymerase chain reaction analysis were performed on paraffin tissue sections to assess loss of heterozygosity (LOH) and microsatellite instability on chromosome 3p, 5q, and 9p. Histology and molecular status at baseline were compared between 7 lesions that became invasive, 11 that relapsed after treatment, 17 that were eradicated with local treatment, and 19 that spontaneously regressed. Measurements and Main Results Ninety-four percent of lesions that progressed or relapsed were CIS at baseline, whereas 79% of spontaneously regressing lesions were severe dysplasia (P &lt; 0.0001). 3p and 9p LOH was more frequent in CIS than in severe dysplasia (P = 0.03). In the whole group of lesions as well as in the CIS group, 3p LOH was strongly associated with progression (P &lt; 0.0001 and P = 0.02, respectively). Microsatellite instability was not associated with the outcome of the lesions. A therapeutic strategy based on the presence of 3p or 9p LOH would have led to overtreatment of six lesions but would have missed only 1 among the 18 progressing lesions. Conclusions Baseline histology and 3p LOH analysis appear to be useful in predicting the outcome of high-grade precancerous lesions.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Canadian journal of kidney health and disease · 2023 · Journal Article
Noor ST, Bota SE, Clarke AE, Petrcich W, et al.
Journal of thoracic disease · 2022 · Journal Article
Lachkar S, Gervereau D, Lanquetuit M, Thiberville L, et al.
Journal of thoracic disease · 2020 · Journal Article
Lachkar S, Guisier F, Roger M, Bota S, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017 · Journal Article
Basse C, Thureau S, Bota S, Dansin E, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011 · Journal Article
Decroisette C, Monnet I, Berard H, Quere G, et al.
American journal of respiratory and critical care medicine · 2008 · Journal Article
Salaün M, Sesboüé R, Moreno-Swirc S, Metayer J, et al.
The European respiratory journal · 2022 · Journal Article
Guisier F, Deslee G, Birembaut P, Escarguel B, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016 · Clinical Trial, Phase III
Corre R, Greillier L, Le Caër H, Audigier-Valette C, et al.
Clinical lung cancer · 2024 · Case Reports
Rousseau G, Dantoing E, Léturgie B, Tillon-Strozyk J, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016 · Clinical Trial, Phase III
Corre R, Greillier L, Le Caër H, Audigier-Valette C, et al.
Clinical lung cancer · 2024 · Case Reports
Rousseau G, Dantoing E, Léturgie B, Tillon-Strozyk J, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011 · Clinical Trial, Phase III
Vergnenegre A, Corre R, Berard H, Paillotin D, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011 · Clinical Trial, Phase III
Vergnenegre A, Corre R, Berard H, Paillotin D, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011 · Clinical Trial, Phase III
Vergnenegre A, Corre R, Berard H, Paillotin D, et al.